| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bayes Theorem | 25 | 2022 | 1021 | 2.090 |
Why?
|
| Software | 10 | 2023 | 1321 | 1.430 |
Why?
|
| Gene Regulatory Networks | 5 | 2018 | 677 | 1.170 |
Why?
|
| Gene Expression Profiling | 15 | 2024 | 5159 | 1.160 |
Why?
|
| Models, Statistical | 10 | 2016 | 1171 | 1.150 |
Why?
|
| Microbiota | 7 | 2024 | 547 | 0.920 |
Why?
|
| Nanotubes | 1 | 2023 | 28 | 0.890 |
Why?
|
| Computational Biology | 3 | 2020 | 1271 | 0.880 |
Why?
|
| Myelodysplastic Syndromes | 10 | 2022 | 2979 | 0.870 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 6 | 2022 | 426 | 0.800 |
Why?
|
| Models, Theoretical | 2 | 2016 | 785 | 0.800 |
Why?
|
| Genomics | 9 | 2022 | 2738 | 0.770 |
Why?
|
| Glioblastoma | 5 | 2016 | 1797 | 0.740 |
Why?
|
| Prostatic Neoplasms | 30 | 2016 | 5767 | 0.730 |
Why?
|
| Breast Neoplasms | 32 | 2021 | 15694 | 0.700 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 470 | 0.680 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2014 | 2508 | 0.660 |
Why?
|
| Stomatitis | 3 | 2023 | 183 | 0.610 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 3 | 2022 | 33 | 0.600 |
Why?
|
| Computer Simulation | 13 | 2023 | 1529 | 0.600 |
Why?
|
| Pancreatic Neoplasms | 10 | 2024 | 5061 | 0.590 |
Why?
|
| Biomarkers, Tumor | 28 | 2022 | 10331 | 0.580 |
Why?
|
| Humans | 199 | 2024 | 261506 | 0.560 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2023 | 907 | 0.540 |
Why?
|
| Kidney Neoplasms | 4 | 2016 | 3022 | 0.470 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 14 | 2018 | 2390 | 0.470 |
Why?
|
| Models, Genetic | 4 | 2015 | 1113 | 0.470 |
Why?
|
| Neoplasm Metastasis | 12 | 2020 | 5112 | 0.460 |
Why?
|
| Systems Integration | 1 | 2013 | 76 | 0.460 |
Why?
|
| Angiography | 1 | 2015 | 360 | 0.460 |
Why?
|
| Disease Progression | 14 | 2023 | 6682 | 0.450 |
Why?
|
| TOR Serine-Threonine Kinases | 8 | 2018 | 1546 | 0.440 |
Why?
|
| Menopause | 4 | 2000 | 159 | 0.420 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 361 | 0.420 |
Why?
|
| Proto-Oncogene Proteins c-akt | 8 | 2019 | 2054 | 0.420 |
Why?
|
| CA-19-9 Antigen | 2 | 2023 | 144 | 0.410 |
Why?
|
| Middle Aged | 100 | 2021 | 86204 | 0.400 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 2 | 2023 | 141 | 0.400 |
Why?
|
| Neoplasms | 13 | 2024 | 15193 | 0.390 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2016 | 1678 | 0.390 |
Why?
|
| Signal Transduction | 14 | 2018 | 11965 | 0.390 |
Why?
|
| Peptide Library | 7 | 2013 | 158 | 0.380 |
Why?
|
| Proteomics | 8 | 2023 | 1380 | 0.380 |
Why?
|
| Sirolimus | 6 | 2015 | 814 | 0.370 |
Why?
|
| Proportional Hazards Models | 26 | 2019 | 4988 | 0.370 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2024 | 1724 | 0.370 |
Why?
|
| Head and Neck Neoplasms | 7 | 2023 | 3976 | 0.370 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 5 | 2019 | 521 | 0.360 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2020 | 1215 | 0.360 |
Why?
|
| Neoplasm Proteins | 6 | 2021 | 3230 | 0.350 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 2 | 2022 | 113 | 0.350 |
Why?
|
| Aged | 79 | 2021 | 70117 | 0.340 |
Why?
|
| Biometry | 3 | 2015 | 241 | 0.340 |
Why?
|
| Opioid-Related Disorders | 2 | 2024 | 394 | 0.330 |
Why?
|
| Female | 101 | 2022 | 141928 | 0.330 |
Why?
|
| DNA Copy Number Variations | 4 | 2022 | 1516 | 0.310 |
Why?
|
| MicroRNAs | 4 | 2015 | 2947 | 0.310 |
Why?
|
| Peptides | 5 | 2019 | 1479 | 0.300 |
Why?
|
| Smoking | 5 | 2004 | 2440 | 0.300 |
Why?
|
| Cyclin E | 2 | 2021 | 267 | 0.300 |
Why?
|
| Neoplasms, Second Primary | 3 | 2004 | 1350 | 0.290 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2019 | 146 | 0.290 |
Why?
|
| Lung Neoplasms | 8 | 2023 | 11538 | 0.290 |
Why?
|
| Mass Screening | 4 | 2022 | 1509 | 0.290 |
Why?
|
| Male | 90 | 2023 | 123000 | 0.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 18 | 2020 | 15862 | 0.280 |
Why?
|
| Regression Analysis | 5 | 2016 | 1546 | 0.280 |
Why?
|
| Neuroendocrine Tumors | 2 | 2023 | 634 | 0.280 |
Why?
|
| Adult | 71 | 2022 | 77950 | 0.280 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2020 | 6915 | 0.270 |
Why?
|
| Androgen Antagonists | 4 | 2009 | 411 | 0.270 |
Why?
|
| Transcriptome | 4 | 2024 | 1859 | 0.270 |
Why?
|
| Early Detection of Cancer | 3 | 2023 | 1258 | 0.260 |
Why?
|
| Aged, 80 and over | 44 | 2021 | 29902 | 0.260 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2016 | 1039 | 0.260 |
Why?
|
| Antigens, Neoplasm | 7 | 2016 | 1506 | 0.250 |
Why?
|
| Liver Neoplasms | 5 | 2017 | 4557 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2021 | 8873 | 0.250 |
Why?
|
| Mutation | 16 | 2022 | 15179 | 0.250 |
Why?
|
| Prostate-Specific Antigen | 6 | 2009 | 993 | 0.250 |
Why?
|
| Monte Carlo Method | 5 | 2015 | 671 | 0.250 |
Why?
|
| beta 2-Microglobulin | 5 | 2009 | 184 | 0.250 |
Why?
|
| Antineoplastic Agents | 14 | 2023 | 14289 | 0.250 |
Why?
|
| Proteome | 3 | 2018 | 561 | 0.240 |
Why?
|
| Receptors, Estrogen | 9 | 2015 | 2086 | 0.240 |
Why?
|
| Cell Line, Tumor | 22 | 2021 | 14551 | 0.240 |
Why?
|
| Prognosis | 35 | 2021 | 21713 | 0.240 |
Why?
|
| Receptors, Progesterone | 7 | 2012 | 1392 | 0.240 |
Why?
|
| Survival Analysis | 16 | 2014 | 9180 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2023 | 5437 | 0.240 |
Why?
|
| Isotretinoin | 2 | 2006 | 158 | 0.230 |
Why?
|
| Prebiotics | 1 | 2023 | 34 | 0.230 |
Why?
|
| Neoplasm Staging | 20 | 2021 | 13658 | 0.230 |
Why?
|
| Algorithms | 9 | 2022 | 3890 | 0.230 |
Why?
|
| Cell Proliferation | 14 | 2021 | 7226 | 0.230 |
Why?
|
| Disease-Free Survival | 19 | 2020 | 10001 | 0.230 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2014 | 4549 | 0.230 |
Why?
|
| Cluster Analysis | 8 | 2022 | 1053 | 0.230 |
Why?
|
| Autoantibodies | 2 | 2019 | 576 | 0.230 |
Why?
|
| Gene Library | 2 | 2023 | 294 | 0.230 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2021 | 3552 | 0.220 |
Why?
|
| Ecosystem | 1 | 2024 | 111 | 0.220 |
Why?
|
| Mucositis | 1 | 2023 | 148 | 0.220 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2018 | 5178 | 0.220 |
Why?
|
| Twins | 3 | 2000 | 70 | 0.220 |
Why?
|
| Mice | 27 | 2023 | 34495 | 0.210 |
Why?
|
| Alcohol Drinking | 2 | 2003 | 551 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 7 | 2021 | 4975 | 0.210 |
Why?
|
| Proteogenomics | 1 | 2023 | 87 | 0.210 |
Why?
|
| Data Interpretation, Statistical | 3 | 2020 | 482 | 0.210 |
Why?
|
| Sample Size | 2 | 2020 | 202 | 0.210 |
Why?
|
| Azacitidine | 3 | 2022 | 1149 | 0.210 |
Why?
|
| Purines | 3 | 2016 | 273 | 0.210 |
Why?
|
| Vidarabine | 5 | 2014 | 1341 | 0.210 |
Why?
|
| Obesity | 6 | 2023 | 2884 | 0.210 |
Why?
|
| Statistics, Nonparametric | 3 | 2021 | 980 | 0.210 |
Why?
|
| Stearoyl-CoA Desaturase | 2 | 2012 | 20 | 0.210 |
Why?
|
| Sequence Analysis, RNA | 2 | 2022 | 651 | 0.200 |
Why?
|
| Polyamines | 1 | 2021 | 75 | 0.200 |
Why?
|
| Bone Marrow | 7 | 2021 | 2358 | 0.200 |
Why?
|
| Gene Expression | 5 | 2020 | 3570 | 0.200 |
Why?
|
| Isochromosomes | 1 | 2021 | 55 | 0.200 |
Why?
|
| Dioxygenases | 1 | 2022 | 159 | 0.200 |
Why?
|
| Genome | 2 | 2022 | 672 | 0.200 |
Why?
|
| Australia | 11 | 2015 | 225 | 0.200 |
Why?
|
| Quality Control | 1 | 2023 | 457 | 0.200 |
Why?
|
| Metabolic Networks and Pathways | 3 | 2018 | 336 | 0.200 |
Why?
|
| Bone Neoplasms | 6 | 2015 | 2576 | 0.200 |
Why?
|
| Cyclophosphamide | 7 | 2014 | 3001 | 0.200 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2019 | 149 | 0.200 |
Why?
|
| Proteoglycans | 1 | 2022 | 259 | 0.190 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2021 | 118 | 0.190 |
Why?
|
| Myelopoiesis | 1 | 2021 | 31 | 0.190 |
Why?
|
| Brain Neoplasms | 4 | 2012 | 4849 | 0.190 |
Why?
|
| Markov Chains | 3 | 2015 | 175 | 0.190 |
Why?
|
| Animals | 33 | 2023 | 59536 | 0.190 |
Why?
|
| Duodenal Neoplasms | 1 | 2021 | 138 | 0.190 |
Why?
|
| Vesicular Transport Proteins | 1 | 2022 | 135 | 0.190 |
Why?
|
| Anemia, Sideroblastic | 1 | 2021 | 58 | 0.190 |
Why?
|
| Spermine Synthase | 1 | 2020 | 6 | 0.190 |
Why?
|
| Climacteric | 1 | 2000 | 3 | 0.190 |
Why?
|
| Spermine | 1 | 2020 | 25 | 0.190 |
Why?
|
| Protein Biosynthesis | 2 | 2016 | 889 | 0.190 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 7 | 2014 | 864 | 0.190 |
Why?
|
| Prostate | 5 | 2023 | 1088 | 0.190 |
Why?
|
| Chronic Pain | 1 | 2024 | 238 | 0.180 |
Why?
|
| Thrombocytosis | 1 | 2021 | 121 | 0.180 |
Why?
|
| Neutropenia | 2 | 2022 | 968 | 0.180 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2017 | 2027 | 0.180 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2021 | 114 | 0.180 |
Why?
|
| Machine Learning | 1 | 2022 | 319 | 0.180 |
Why?
|
| Paclitaxel | 6 | 2015 | 1996 | 0.180 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2016 | 2326 | 0.180 |
Why?
|
| Longitudinal Studies | 5 | 2017 | 1945 | 0.180 |
Why?
|
| Research Support as Topic | 1 | 2020 | 122 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2015 | 7551 | 0.180 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2015 | 973 | 0.180 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2021 | 209 | 0.180 |
Why?
|
| Interferon Type I | 1 | 2021 | 250 | 0.180 |
Why?
|
| DNA-Binding Proteins | 3 | 2022 | 4821 | 0.180 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2018 | 142 | 0.170 |
Why?
|
| Biomarkers | 6 | 2023 | 5047 | 0.170 |
Why?
|
| Discriminant Analysis | 1 | 1999 | 48 | 0.170 |
Why?
|
| Adenocarcinoma | 7 | 2021 | 7789 | 0.170 |
Why?
|
| RNA, Messenger | 5 | 2017 | 6150 | 0.170 |
Why?
|
| Sialyltransferases | 1 | 2018 | 23 | 0.170 |
Why?
|
| Cancer Pain | 1 | 2024 | 312 | 0.170 |
Why?
|
| Enema | 1 | 2018 | 47 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2016 | 10035 | 0.160 |
Why?
|
| Up-Regulation | 3 | 2021 | 2450 | 0.160 |
Why?
|
| Treatment Outcome | 29 | 2022 | 32848 | 0.160 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2016 | 1823 | 0.160 |
Why?
|
| Computer Graphics | 1 | 2018 | 82 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 447 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2019 | 4757 | 0.160 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2011 | 106 | 0.160 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2018 | 14 | 0.160 |
Why?
|
| Biological Products | 1 | 2021 | 274 | 0.160 |
Why?
|
| Oligopeptides | 5 | 2013 | 429 | 0.160 |
Why?
|
| Evoked Potentials | 1 | 1999 | 190 | 0.160 |
Why?
|
| Pyrimidines | 4 | 2018 | 3518 | 0.160 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2022 | 519 | 0.160 |
Why?
|
| Systems Biology | 1 | 2018 | 112 | 0.160 |
Why?
|
| Survival Rate | 17 | 2021 | 12221 | 0.160 |
Why?
|
| Protein Interaction Maps | 1 | 2018 | 149 | 0.150 |
Why?
|
| HLA Antigens | 3 | 2007 | 546 | 0.150 |
Why?
|
| Antigens, CD | 5 | 2015 | 1385 | 0.150 |
Why?
|
| Carbamoyl-Phosphate Synthase (Ammonia) | 1 | 2017 | 17 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2021 | 3821 | 0.150 |
Why?
|
| Receptor, ErbB-2 | 7 | 2015 | 2518 | 0.150 |
Why?
|
| Indazoles | 1 | 2018 | 297 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2022 | 1146 | 0.150 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2012 | 986 | 0.150 |
Why?
|
| Genetic Markers | 3 | 2009 | 974 | 0.150 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2018 | 145 | 0.140 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 14889 | 0.140 |
Why?
|
| Blood Vessels | 2 | 2011 | 217 | 0.140 |
Why?
|
| Supervised Machine Learning | 1 | 2016 | 12 | 0.140 |
Why?
|
| Quinazolinones | 1 | 2016 | 51 | 0.140 |
Why?
|
| Finasteride | 1 | 2016 | 31 | 0.140 |
Why?
|
| RNA | 1 | 2021 | 1013 | 0.140 |
Why?
|
| Sensitivity and Specificity | 6 | 2020 | 4971 | 0.140 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2020 | 923 | 0.140 |
Why?
|
| Liver Cirrhosis | 3 | 2017 | 941 | 0.130 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 2006 | 60 | 0.130 |
Why?
|
| Coronary Disease | 1 | 2000 | 764 | 0.130 |
Why?
|
| Aromatase Inhibitors | 1 | 2018 | 305 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 419 | 0.130 |
Why?
|
| Interleukin-11 Receptor alpha Subunit | 1 | 2015 | 14 | 0.130 |
Why?
|
| Hematopoiesis | 1 | 2018 | 560 | 0.130 |
Why?
|
| Immediate-Early Proteins | 1 | 2016 | 107 | 0.130 |
Why?
|
| Taxoids | 4 | 2021 | 967 | 0.130 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2008 | 355 | 0.130 |
Why?
|
| Mice, Nude | 9 | 2015 | 4307 | 0.130 |
Why?
|
| Logistic Models | 8 | 2019 | 3441 | 0.130 |
Why?
|
| DNA Transposable Elements | 1 | 2016 | 222 | 0.130 |
Why?
|
| Hyperglycemia | 2 | 2015 | 333 | 0.130 |
Why?
|
| Clostridium Infections | 1 | 2018 | 252 | 0.130 |
Why?
|
| Antigens, CD20 | 3 | 2006 | 206 | 0.130 |
Why?
|
| Time Factors | 13 | 2020 | 12926 | 0.130 |
Why?
|
| Bleomycin | 3 | 2006 | 467 | 0.120 |
Why?
|
| Salvage Therapy | 4 | 2014 | 2054 | 0.120 |
Why?
|
| ErbB Receptors | 5 | 2016 | 2295 | 0.120 |
Why?
|
| Reproducibility of Results | 8 | 2015 | 6009 | 0.120 |
Why?
|
| Benzoxazoles | 1 | 2014 | 41 | 0.120 |
Why?
|
| alpha-Fetoproteins | 1 | 2015 | 237 | 0.120 |
Why?
|
| Protein Isoforms | 1 | 2016 | 842 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2018 | 677 | 0.120 |
Why?
|
| Chromosome Aberrations | 1 | 2011 | 1960 | 0.120 |
Why?
|
| Introns | 1 | 2015 | 432 | 0.120 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2020 | 490 | 0.120 |
Why?
|
| Risk Factors | 17 | 2013 | 17523 | 0.120 |
Why?
|
| DNA Methylation | 2 | 2015 | 2669 | 0.120 |
Why?
|
| Normal Distribution | 1 | 2013 | 61 | 0.120 |
Why?
|
| Atlases as Topic | 1 | 2013 | 42 | 0.120 |
Why?
|
| Hepatitis C, Chronic | 2 | 2017 | 451 | 0.120 |
Why?
|
| Prostatectomy | 6 | 2009 | 962 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2015 | 445 | 0.120 |
Why?
|
| Medical Oncology | 1 | 2022 | 1423 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2021 | 1664 | 0.110 |
Why?
|
| Case-Control Studies | 8 | 2022 | 6100 | 0.110 |
Why?
|
| DNA Damage | 1 | 2021 | 1954 | 0.110 |
Why?
|
| Mucormycosis | 1 | 2014 | 108 | 0.110 |
Why?
|
| Thalidomide | 2 | 2007 | 569 | 0.110 |
Why?
|
| Antigens, CD19 | 1 | 2016 | 577 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 5319 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2016 | 607 | 0.110 |
Why?
|
| Sulfonamides | 2 | 2020 | 1823 | 0.110 |
Why?
|
| Heterografts | 1 | 2015 | 733 | 0.110 |
Why?
|
| Absorptiometry, Photon | 2 | 2011 | 239 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 582 | 0.110 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2012 | 42 | 0.110 |
Why?
|
| Dietary Fats | 1 | 2014 | 339 | 0.110 |
Why?
|
| Multivariate Analysis | 9 | 2013 | 4298 | 0.110 |
Why?
|
| Genome, Human | 2 | 2019 | 1869 | 0.110 |
Why?
|
| Immunohistochemistry | 10 | 2019 | 7548 | 0.110 |
Why?
|
| Apoptosis | 10 | 2016 | 7591 | 0.110 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2012 | 107 | 0.110 |
Why?
|
| Antibodies, Neoplasm | 2 | 2004 | 259 | 0.110 |
Why?
|
| Colorectal Neoplasms | 3 | 2023 | 3578 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 7 | 2008 | 4367 | 0.110 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 67 | 0.110 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2010 | 105 | 0.110 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2006 | 630 | 0.110 |
Why?
|
| Inflammation | 3 | 2023 | 2522 | 0.110 |
Why?
|
| Cadherins | 3 | 2015 | 660 | 0.110 |
Why?
|
| Microdissection | 3 | 2009 | 86 | 0.110 |
Why?
|
| RNA, Neoplasm | 1 | 2015 | 771 | 0.110 |
Why?
|
| Risk Assessment | 6 | 2024 | 6869 | 0.100 |
Why?
|
| Glycoproteins | 3 | 2004 | 747 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2017 | 6207 | 0.100 |
Why?
|
| Peptidomimetics | 1 | 2011 | 26 | 0.100 |
Why?
|
| Hodgkin Disease | 3 | 2006 | 1429 | 0.100 |
Why?
|
| Cytoplasm | 2 | 2016 | 652 | 0.100 |
Why?
|
| Adolescent | 18 | 2020 | 31252 | 0.100 |
Why?
|
| Nomograms | 3 | 2011 | 313 | 0.100 |
Why?
|
| Predictive Value of Tests | 7 | 2021 | 4892 | 0.100 |
Why?
|
| Diet, Fat-Restricted | 1 | 2011 | 56 | 0.100 |
Why?
|
| Cell Line | 1 | 2019 | 5114 | 0.100 |
Why?
|
| Adipose Tissue, White | 1 | 2011 | 99 | 0.100 |
Why?
|
| Ovarian Neoplasms | 3 | 2022 | 4638 | 0.100 |
Why?
|
| Precancerous Conditions | 1 | 2018 | 1058 | 0.100 |
Why?
|
| Feeding Behavior | 2 | 2014 | 808 | 0.100 |
Why?
|
| Melanoma | 2 | 2009 | 5317 | 0.100 |
Why?
|
| Tumor Burden | 4 | 2021 | 1987 | 0.090 |
Why?
|
| Prospective Studies | 11 | 2021 | 12873 | 0.090 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2010 | 24 | 0.090 |
Why?
|
| Metformin | 1 | 2014 | 378 | 0.090 |
Why?
|
| Cancer Vaccines | 1 | 2016 | 697 | 0.090 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2016 | 713 | 0.090 |
Why?
|
| Physicians | 1 | 2019 | 882 | 0.090 |
Why?
|
| Weight Loss | 2 | 2011 | 627 | 0.090 |
Why?
|
| Receptors, Androgen | 1 | 2016 | 878 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 3 | 2022 | 1290 | 0.090 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2015 | 425 | 0.090 |
Why?
|
| Rituximab | 7 | 2014 | 1528 | 0.090 |
Why?
|
| Mice, SCID | 4 | 2021 | 1869 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 586 | 0.090 |
Why?
|
| Linkage Disequilibrium | 3 | 2013 | 460 | 0.090 |
Why?
|
| Ross River virus | 2 | 2000 | 5 | 0.090 |
Why?
|
| Analysis of Variance | 3 | 2010 | 2307 | 0.090 |
Why?
|
| Transcription Factors | 2 | 2022 | 5270 | 0.090 |
Why?
|
| Disease Models, Animal | 6 | 2016 | 7222 | 0.090 |
Why?
|
| Phosphorylation | 6 | 2018 | 4804 | 0.090 |
Why?
|
| RNA, Long Noncoding | 1 | 2015 | 598 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2016 | 1763 | 0.090 |
Why?
|
| X-Ray Microtomography | 1 | 2010 | 141 | 0.090 |
Why?
|
| Genetic Therapy | 3 | 2016 | 1616 | 0.090 |
Why?
|
| Selenomethionine | 1 | 2009 | 41 | 0.090 |
Why?
|
| MCF-7 Cells | 3 | 2015 | 550 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2022 | 4938 | 0.080 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 3719 | 0.080 |
Why?
|
| Phenotype | 5 | 2022 | 6295 | 0.080 |
Why?
|
| alpha-Tocopherol | 1 | 2009 | 78 | 0.080 |
Why?
|
| RNA Interference | 3 | 2021 | 1408 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2011 | 423 | 0.080 |
Why?
|
| Imidazoles | 2 | 2022 | 999 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2014 | 5539 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 1586 | 0.080 |
Why?
|
| Osteopontin | 1 | 2009 | 148 | 0.080 |
Why?
|
| Genes, BRCA2 | 1 | 2011 | 309 | 0.080 |
Why?
|
| Cohort Studies | 8 | 2019 | 9244 | 0.080 |
Why?
|
| Texas | 6 | 2023 | 6311 | 0.080 |
Why?
|
| Alkaline Phosphatase | 1 | 2009 | 207 | 0.080 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2008 | 101 | 0.080 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2016 | 2796 | 0.080 |
Why?
|
| Artificial Intelligence | 1 | 2012 | 388 | 0.080 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 195 | 0.080 |
Why?
|
| Sugar Alcohol Dehydrogenases | 1 | 2007 | 12 | 0.080 |
Why?
|
| Genes, BRCA1 | 1 | 2011 | 387 | 0.080 |
Why?
|
| Lymphatic Metastasis | 4 | 2011 | 4844 | 0.080 |
Why?
|
| Educational Status | 2 | 2000 | 397 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 4314 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2008 | 852 | 0.080 |
Why?
|
| Ki-67 Antigen | 3 | 2011 | 666 | 0.080 |
Why?
|
| Testicular Neoplasms | 2 | 2002 | 529 | 0.080 |
Why?
|
| Metabolome | 2 | 2024 | 344 | 0.080 |
Why?
|
| Receptor, ErbB-3 | 1 | 2008 | 122 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2007 | 1248 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2008 | 153 | 0.080 |
Why?
|
| Serine Endopeptidases | 1 | 2008 | 275 | 0.080 |
Why?
|
| Dipeptides | 1 | 2007 | 91 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 4654 | 0.070 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2008 | 315 | 0.070 |
Why?
|
| Alzheimer Disease | 1 | 2015 | 855 | 0.070 |
Why?
|
| Double-Blind Method | 4 | 2019 | 2588 | 0.070 |
Why?
|
| Liver | 4 | 2015 | 2961 | 0.070 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 362 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2022 | 6550 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2010 | 619 | 0.070 |
Why?
|
| Cytokines | 2 | 2016 | 2809 | 0.070 |
Why?
|
| Placebos | 3 | 2019 | 437 | 0.070 |
Why?
|
| Molecular Sequence Data | 5 | 2015 | 6089 | 0.070 |
Why?
|
| Feces | 2 | 2020 | 770 | 0.070 |
Why?
|
| Age Factors | 5 | 2006 | 5377 | 0.070 |
Why?
|
| Cryotherapy | 1 | 2006 | 67 | 0.070 |
Why?
|
| Risk | 3 | 2006 | 1972 | 0.070 |
Why?
|
| Drug Administration Schedule | 5 | 2015 | 3472 | 0.070 |
Why?
|
| Lymphocyte Count | 1 | 2007 | 486 | 0.070 |
Why?
|
| Life Style | 3 | 2015 | 612 | 0.070 |
Why?
|
| Environmental Pollution | 1 | 2006 | 19 | 0.070 |
Why?
|
| Retrospective Studies | 14 | 2021 | 37905 | 0.070 |
Why?
|
| Anthracyclines | 2 | 2021 | 331 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2011 | 731 | 0.070 |
Why?
|
| Urethral Neoplasms | 1 | 2006 | 60 | 0.070 |
Why?
|
| Mutagens | 1 | 2006 | 187 | 0.070 |
Why?
|
| Vinblastine | 2 | 2008 | 453 | 0.070 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2012 | 1216 | 0.070 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2012 | 716 | 0.070 |
Why?
|
| Splenic Neoplasms | 1 | 2006 | 119 | 0.070 |
Why?
|
| Young Adult | 7 | 2021 | 21445 | 0.070 |
Why?
|
| Urethra | 1 | 2006 | 144 | 0.070 |
Why?
|
| Venous Thromboembolism | 1 | 2010 | 335 | 0.070 |
Why?
|
| Amino Acid Sequence | 5 | 2015 | 4233 | 0.070 |
Why?
|
| Neoplasm Grading | 3 | 2016 | 1742 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2008 | 1489 | 0.070 |
Why?
|
| Schizophrenia | 1 | 2008 | 369 | 0.060 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2006 | 137 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2007 | 408 | 0.060 |
Why?
|
| Triglycerides | 2 | 2014 | 603 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 3 | 2011 | 1547 | 0.060 |
Why?
|
| Body Mass Index | 3 | 2005 | 2203 | 0.060 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 2265 | 0.060 |
Why?
|
| Recurrence | 6 | 2010 | 4758 | 0.060 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2004 | 87 | 0.060 |
Why?
|
| Protein Array Analysis | 3 | 2015 | 501 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2010 | 787 | 0.060 |
Why?
|
| Pandemics | 2 | 2024 | 1559 | 0.060 |
Why?
|
| Diphosphonates | 1 | 2006 | 262 | 0.060 |
Why?
|
| Early Diagnosis | 2 | 2016 | 298 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2011 | 1549 | 0.060 |
Why?
|
| Dentists | 1 | 2023 | 10 | 0.060 |
Why?
|
| Proteins | 2 | 2022 | 1963 | 0.060 |
Why?
|
| Analgesics, Opioid | 2 | 2024 | 1371 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 657 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2023 | 2488 | 0.060 |
Why?
|
| Mastectomy | 1 | 2010 | 1534 | 0.060 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2003 | 13 | 0.060 |
Why?
|
| Remission Induction | 6 | 2008 | 3569 | 0.060 |
Why?
|
| Pancreas | 2 | 2023 | 718 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 3869 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 3639 | 0.060 |
Why?
|
| Menarche | 2 | 2000 | 50 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2018 | 1544 | 0.060 |
Why?
|
| Endothelial Cells | 2 | 2006 | 1048 | 0.060 |
Why?
|
| Osteoarthritis, Hip | 2 | 1999 | 17 | 0.060 |
Why?
|
| Amino Acid Motifs | 3 | 2011 | 392 | 0.060 |
Why?
|
| Insecticides | 1 | 2003 | 49 | 0.060 |
Why?
|
| Verrucomicrobia | 1 | 2022 | 26 | 0.060 |
Why?
|
| Professional Role | 1 | 2023 | 78 | 0.060 |
Why?
|
| Propionates | 1 | 2022 | 71 | 0.060 |
Why?
|
| Solubility | 3 | 2008 | 242 | 0.060 |
Why?
|
| Models, Biological | 3 | 2018 | 3254 | 0.050 |
Why?
|
| Registries | 3 | 2019 | 2170 | 0.050 |
Why?
|
| Mucus | 1 | 2022 | 119 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 2594 | 0.050 |
Why?
|
| Western World | 1 | 2002 | 8 | 0.050 |
Why?
|
| Decision Making | 1 | 2010 | 1287 | 0.050 |
Why?
|
| Flow Cytometry | 4 | 2018 | 3033 | 0.050 |
Why?
|
| Catalytic Domain | 2 | 2014 | 303 | 0.050 |
Why?
|
| Sesquiterpenes | 1 | 2002 | 68 | 0.050 |
Why?
|
| Aedes | 2 | 2000 | 92 | 0.050 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2022 | 52 | 0.050 |
Why?
|
| Body Surface Area | 1 | 2002 | 42 | 0.050 |
Why?
|
| Weight Gain | 1 | 2005 | 464 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2006 | 1144 | 0.050 |
Why?
|
| Carboxylesterase | 1 | 2021 | 33 | 0.050 |
Why?
|
| Seminoma | 1 | 2002 | 81 | 0.050 |
Why?
|
| Germinoma | 1 | 2002 | 84 | 0.050 |
Why?
|
| Epoxide Hydrolases | 1 | 2021 | 53 | 0.050 |
Why?
|
| Doxorubicin | 3 | 2008 | 3005 | 0.050 |
Why?
|
| Lactation | 1 | 2003 | 210 | 0.050 |
Why?
|
| Leukemia, Myeloid | 1 | 2007 | 941 | 0.050 |
Why?
|
| NAD+ Nucleosidase | 1 | 2001 | 17 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2022 | 132 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 4143 | 0.050 |
Why?
|
| Biocatalysis | 1 | 2021 | 63 | 0.050 |
Why?
|
| CA-125 Antigen | 1 | 2022 | 226 | 0.050 |
Why?
|
| Mucins | 1 | 2022 | 285 | 0.050 |
Why?
|
| Combinatorial Chemistry Techniques | 2 | 2015 | 37 | 0.050 |
Why?
|
| Endosonography | 1 | 2005 | 536 | 0.050 |
Why?
|
| Lung | 2 | 2023 | 3151 | 0.050 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2002 | 177 | 0.050 |
Why?
|
| Blotting, Western | 4 | 2010 | 3536 | 0.050 |
Why?
|
| Ligands | 3 | 2011 | 995 | 0.050 |
Why?
|
| Lymphocyte Activation | 2 | 2016 | 1688 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2017 | 760 | 0.050 |
Why?
|
| Biopsy | 3 | 2021 | 3443 | 0.050 |
Why?
|
| Precision Medicine | 2 | 2019 | 1154 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2006 | 448 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2008 | 1491 | 0.050 |
Why?
|
| Dinoprostone | 1 | 2002 | 208 | 0.050 |
Why?
|
| Genomic Structural Variation | 1 | 2011 | 77 | 0.050 |
Why?
|
| Ecology | 1 | 2020 | 13 | 0.050 |
Why?
|
| Protein Kinases | 2 | 2019 | 874 | 0.050 |
Why?
|
| Piperazines | 2 | 2008 | 2101 | 0.050 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2001 | 133 | 0.050 |
Why?
|
| DNA Repair | 1 | 2009 | 1872 | 0.050 |
Why?
|
| Everolimus | 2 | 2014 | 415 | 0.050 |
Why?
|
| Osteoarthritis, Knee | 2 | 1999 | 162 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2021 | 3890 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2003 | 519 | 0.050 |
Why?
|
| Victoria | 1 | 2000 | 17 | 0.050 |
Why?
|
| Sarcoma | 2 | 2009 | 1725 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2020 | 2292 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2001 | 238 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 1999 | 756 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 187 | 0.050 |
Why?
|
| Immunity | 1 | 2022 | 342 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2021 | 5710 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2020 | 158 | 0.050 |
Why?
|
| Carcinoma | 2 | 2010 | 2578 | 0.050 |
Why?
|
| Parity | 1 | 2000 | 139 | 0.050 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2019 | 39 | 0.050 |
Why?
|
| Intestinal Mucosa | 2 | 2006 | 1081 | 0.050 |
Why?
|
| Pancreatitis, Chronic | 1 | 2020 | 116 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 2012 | 1082 | 0.040 |
Why?
|
| Metabolomics | 1 | 2023 | 478 | 0.040 |
Why?
|
| Adenosine Triphosphatases | 1 | 2002 | 435 | 0.040 |
Why?
|
| Pancreatic Cyst | 1 | 2020 | 107 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2008 | 1390 | 0.040 |
Why?
|
| Cytarabine | 3 | 2020 | 1973 | 0.040 |
Why?
|
| Alphavirus Infections | 1 | 1999 | 11 | 0.040 |
Why?
|
| Microsatellite Repeats | 2 | 1998 | 575 | 0.040 |
Why?
|
| Conflict of Interest | 1 | 2020 | 98 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2004 | 1090 | 0.040 |
Why?
|
| Research Design | 2 | 2022 | 1544 | 0.040 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 1999 | 24 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2000 | 233 | 0.040 |
Why?
|
| Annexins | 1 | 2019 | 5 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2002 | 577 | 0.040 |
Why?
|
| Diseases in Twins | 1 | 1999 | 99 | 0.040 |
Why?
|
| Hemochromatosis | 1 | 1999 | 35 | 0.040 |
Why?
|
| Rheumatic Fever | 1 | 1999 | 18 | 0.040 |
Why?
|
| Probability | 1 | 2021 | 866 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2003 | 2218 | 0.040 |
Why?
|
| Rheumatology | 1 | 1999 | 72 | 0.040 |
Why?
|
| Freeze Drying | 1 | 2018 | 30 | 0.040 |
Why?
|
| Culicidae | 1 | 1999 | 68 | 0.040 |
Why?
|
| Daunorubicin | 1 | 2020 | 301 | 0.040 |
Why?
|
| Osteoarthritis | 1 | 1999 | 94 | 0.040 |
Why?
|
| Capsules | 1 | 2018 | 53 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 342 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 905 | 0.040 |
Why?
|
| Smoking Cessation | 1 | 2004 | 712 | 0.040 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2002 | 328 | 0.040 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2006 | 962 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2011 | 299 | 0.040 |
Why?
|
| Insect Vectors | 1 | 1999 | 110 | 0.040 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1999 | 122 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2000 | 341 | 0.040 |
Why?
|
| Blotting, Northern | 2 | 2010 | 682 | 0.040 |
Why?
|
| Social Class | 1 | 2000 | 310 | 0.040 |
Why?
|
| Membrane Glycoproteins | 2 | 2020 | 1073 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2011 | 7702 | 0.040 |
Why?
|
| Hysterectomy | 2 | 1999 | 611 | 0.040 |
Why?
|
| United States | 4 | 2021 | 15433 | 0.040 |
Why?
|
| Aspirin | 1 | 2002 | 455 | 0.040 |
Why?
|
| Health Personnel | 1 | 2024 | 625 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1999 | 235 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2001 | 1225 | 0.040 |
Why?
|
| Kidney | 3 | 2015 | 2146 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 309 | 0.040 |
Why?
|
| Breast | 2 | 2018 | 1344 | 0.040 |
Why?
|
| Streptococcus pyogenes | 1 | 1999 | 119 | 0.040 |
Why?
|
| Gangliosides | 1 | 2018 | 95 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2019 | 593 | 0.040 |
Why?
|
| Brain | 2 | 2008 | 4113 | 0.040 |
Why?
|
| Birth Weight | 1 | 2000 | 374 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2018 | 175 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2003 | 1294 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 368 | 0.040 |
Why?
|
| Cisplatin | 2 | 2002 | 2432 | 0.040 |
Why?
|
| Combined Modality Therapy | 5 | 2007 | 8865 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2018 | 90 | 0.040 |
Why?
|
| Lymphoma | 1 | 2006 | 1467 | 0.040 |
Why?
|
| Glioma | 1 | 2009 | 1963 | 0.040 |
Why?
|
| Skull Base Neoplasms | 1 | 2001 | 314 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1998 | 317 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2019 | 333 | 0.040 |
Why?
|
| Body Weight | 1 | 2002 | 1293 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2018 | 242 | 0.040 |
Why?
|
| Methylation | 1 | 2018 | 597 | 0.040 |
Why?
|
| Pemetrexed | 1 | 2017 | 102 | 0.040 |
Why?
|
| Hepatectomy | 2 | 2001 | 1011 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2012 | 726 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 669 | 0.040 |
Why?
|
| Antigens, Bacterial | 1 | 1999 | 354 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2018 | 557 | 0.040 |
Why?
|
| Odds Ratio | 3 | 2011 | 2316 | 0.040 |
Why?
|
| Epitopes | 1 | 1999 | 685 | 0.040 |
Why?
|
| Age of Onset | 1 | 1998 | 827 | 0.040 |
Why?
|
| Rectal Neoplasms | 1 | 2005 | 1202 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 3 | 2010 | 3203 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 702 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2000 | 565 | 0.030 |
Why?
|
| Cell Survival | 2 | 2018 | 3045 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 4744 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2016 | 107 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2016 | 629 | 0.030 |
Why?
|
| Thiophenes | 1 | 2017 | 148 | 0.030 |
Why?
|
| Mouth Neoplasms | 1 | 2001 | 713 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2021 | 1732 | 0.030 |
Why?
|
| Drug Resistance, Multiple | 2 | 2006 | 204 | 0.030 |
Why?
|
| Lasers | 2 | 2007 | 198 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2015 | 2314 | 0.030 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 1999 | 274 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 1999 | 1471 | 0.030 |
Why?
|
| Homozygote | 2 | 2013 | 717 | 0.030 |
Why?
|
| Urea | 1 | 2017 | 290 | 0.030 |
Why?
|
| alpha-2-HS-Glycoprotein | 1 | 2015 | 10 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2015 | 120 | 0.030 |
Why?
|
| Cell Surface Display Techniques | 1 | 2015 | 17 | 0.030 |
Why?
|
| Adenosine Deaminase | 1 | 2015 | 94 | 0.030 |
Why?
|
| Hematologic Diseases | 2 | 2002 | 242 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2018 | 597 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2016 | 284 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2007 | 223 | 0.030 |
Why?
|
| Peptide Mapping | 1 | 2015 | 114 | 0.030 |
Why?
|
| Egypt | 2 | 2006 | 42 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2007 | 1533 | 0.030 |
Why?
|
| Bacteria | 1 | 2019 | 611 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2023 | 1303 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2015 | 159 | 0.030 |
Why?
|
| Allosteric Regulation | 1 | 2014 | 68 | 0.030 |
Why?
|
| RNA Precursors | 1 | 2015 | 137 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1440 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2014 | 68 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2016 | 626 | 0.030 |
Why?
|
| Rhizopus | 1 | 2014 | 39 | 0.030 |
Why?
|
| CD52 Antigen | 2 | 2004 | 46 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase 1 | 2 | 2007 | 141 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2016 | 288 | 0.030 |
Why?
|
| Proteinuria | 1 | 2015 | 155 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 2001 | 927 | 0.030 |
Why?
|
| Plasmids | 1 | 2016 | 837 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2009 | 1391 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2016 | 374 | 0.030 |
Why?
|
| Antigen-Antibody Reactions | 2 | 2004 | 92 | 0.030 |
Why?
|
| Epirubicin | 1 | 2014 | 157 | 0.030 |
Why?
|
| DNA Replication | 1 | 1998 | 744 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 1077 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2000 | 1467 | 0.030 |
Why?
|
| Stathmin | 1 | 2013 | 30 | 0.030 |
Why?
|
| Ribosomal Protein S6 | 1 | 2013 | 46 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 1999 | 1152 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 1879 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2018 | 667 | 0.030 |
Why?
|
| Random Allocation | 2 | 2006 | 703 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 3 | 2007 | 5395 | 0.030 |
Why?
|
| Stromal Cells | 2 | 2008 | 825 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 886 | 0.030 |
Why?
|
| RNA, Small Interfering | 2 | 2010 | 2216 | 0.030 |
Why?
|
| Incidence | 3 | 2011 | 5673 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2015 | 314 | 0.030 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2013 | 16 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2014 | 265 | 0.030 |
Why?
|
| Survival | 1 | 2013 | 177 | 0.030 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2013 | 54 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2006 | 2341 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 460 | 0.030 |
Why?
|
| Linear Models | 2 | 2009 | 1085 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 6942 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 371 | 0.030 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2012 | 16 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2013 | 89 | 0.030 |
Why?
|
| Chromatin | 1 | 2018 | 942 | 0.030 |
Why?
|
| Plasminogen Activators | 1 | 2012 | 52 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 1999 | 1029 | 0.030 |
Why?
|
| Pyridones | 1 | 2015 | 348 | 0.030 |
Why?
|
| Bridged-Ring Compounds | 1 | 2013 | 183 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2014 | 241 | 0.030 |
Why?
|
| Imatinib Mesylate | 2 | 2008 | 1665 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2015 | 256 | 0.030 |
Why?
|
| Interleukin-13 | 1 | 2013 | 135 | 0.030 |
Why?
|
| Organ Specificity | 2 | 2006 | 699 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 101 | 0.030 |
Why?
|
| Haplotypes | 2 | 2009 | 856 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2013 | 284 | 0.030 |
Why?
|
| Barrett Esophagus | 1 | 1998 | 569 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 1242 | 0.030 |
Why?
|
| Cercopithecidae | 1 | 2011 | 10 | 0.030 |
Why?
|
| Annexin A4 | 1 | 2011 | 7 | 0.030 |
Why?
|
| Apolipoprotein E3 | 1 | 2011 | 16 | 0.030 |
Why?
|
| Integrin alpha4 | 1 | 2011 | 25 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2014 | 395 | 0.030 |
Why?
|
| Drug Design | 1 | 2014 | 375 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2012 | 355 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 848 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2018 | 1026 | 0.030 |
Why?
|
| Receptors, Calcitriol | 1 | 2012 | 134 | 0.030 |
Why?
|
| Cathepsin B | 1 | 2011 | 32 | 0.030 |
Why?
|
| Leukemia | 1 | 2020 | 1635 | 0.030 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2014 | 221 | 0.030 |
Why?
|
| Flax | 1 | 2011 | 3 | 0.030 |
Why?
|
| Immunotherapy | 2 | 2020 | 3341 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2015 | 1643 | 0.030 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2011 | 102 | 0.030 |
Why?
|
| Benzamides | 2 | 2008 | 1832 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2012 | 200 | 0.030 |
Why?
|
| Antibodies | 1 | 2015 | 838 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 612 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2017 | 1353 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2011 | 192 | 0.020 |
Why?
|
| Histones | 1 | 2018 | 1466 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2016 | 1620 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 2864 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2015 | 1489 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2013 | 481 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2000 | 5687 | 0.020 |
Why?
|
| Anthropometry | 1 | 2011 | 269 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 4320 | 0.020 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2011 | 247 | 0.020 |
Why?
|
| Hospital Design and Construction | 1 | 1990 | 12 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 1999 | 2022 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 649 | 0.020 |
Why?
|
| Genotype | 2 | 2009 | 4109 | 0.020 |
Why?
|
| Calcification, Physiologic | 1 | 2010 | 56 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2016 | 2084 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 1178 | 0.020 |
Why?
|
| Chi-Square Distribution | 2 | 2005 | 1323 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2018 | 1443 | 0.020 |
Why?
|
| Transfection | 1 | 2015 | 2944 | 0.020 |
Why?
|
| Causality | 1 | 2010 | 178 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 2291 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2016 | 2843 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 1143 | 0.020 |
Why?
|
| Culex | 2 | 2000 | 30 | 0.020 |
Why?
|
| Cognitive Dysfunction | 1 | 2015 | 333 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2012 | 1618 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2014 | 1944 | 0.020 |
Why?
|
| Twins, Dizygotic | 2 | 2000 | 49 | 0.020 |
Why?
|
| Genes, src | 1 | 2009 | 27 | 0.020 |
Why?
|
| Femur | 1 | 2010 | 158 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2012 | 1163 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2009 | 62 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2012 | 829 | 0.020 |
Why?
|
| Canada | 1 | 2010 | 429 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2012 | 1313 | 0.020 |
Why?
|
| Estramustine | 1 | 2008 | 26 | 0.020 |
Why?
|
| Ketoconazole | 1 | 2008 | 34 | 0.020 |
Why?
|
| DNA Ligase ATP | 1 | 2009 | 51 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 1165 | 0.020 |
Why?
|
| Dominance, Cerebral | 1 | 2008 | 81 | 0.020 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2009 | 66 | 0.020 |
Why?
|
| DNA Ligases | 1 | 2009 | 63 | 0.020 |
Why?
|
| Twins, Monozygotic | 2 | 2000 | 129 | 0.020 |
Why?
|
| Cerebral Ventricles | 1 | 2008 | 98 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1999 | 2819 | 0.020 |
Why?
|
| Fatigue | 1 | 2015 | 1239 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 649 | 0.020 |
Why?
|
| Alleles | 2 | 2008 | 2437 | 0.020 |
Why?
|
| Protein Binding | 1 | 2015 | 3438 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2010 | 226 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2014 | 829 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2009 | 172 | 0.020 |
Why?
|
| Lymph Nodes | 2 | 2011 | 2967 | 0.020 |
Why?
|
| Glucose | 1 | 2014 | 1248 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2010 | 216 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 1399 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 1084 | 0.020 |
Why?
|
| Observer Variation | 2 | 1999 | 671 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2009 | 170 | 0.020 |
Why?
|
| Endonucleases | 1 | 2009 | 178 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2008 | 157 | 0.020 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2013 | 509 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 2403 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2013 | 769 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2009 | 237 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2007 | 190 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2006 | 3981 | 0.020 |
Why?
|
| Skin | 1 | 2013 | 1259 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 324 | 0.020 |
Why?
|
| Bone Density | 1 | 2010 | 476 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2007 | 257 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2011 | 558 | 0.020 |
Why?
|
| Chromatids | 1 | 2006 | 78 | 0.020 |
Why?
|
| Mycoses | 1 | 1990 | 386 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 1442 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2010 | 745 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 143 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2008 | 304 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2009 | 1008 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2006 | 153 | 0.020 |
Why?
|
| Receptors, Prolactin | 1 | 2006 | 27 | 0.020 |
Why?
|
| Lacrimal Duct Obstruction | 1 | 2006 | 53 | 0.020 |
Why?
|
| Topotecan | 1 | 2007 | 239 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2006 | 133 | 0.020 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2006 | 104 | 0.020 |
Why?
|
| Actins | 1 | 2009 | 608 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 1656 | 0.020 |
Why?
|
| Urologic Surgical Procedures | 1 | 2006 | 93 | 0.020 |
Why?
|
| Splenectomy | 1 | 2006 | 158 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 2008 | 443 | 0.020 |
Why?
|
| Microcirculation | 1 | 2006 | 200 | 0.020 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2005 | 93 | 0.020 |
Why?
|
| Tibia | 1 | 2006 | 131 | 0.020 |
Why?
|
| Cross Infection | 1 | 1990 | 544 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2008 | 588 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2006 | 224 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 2483 | 0.020 |
Why?
|
| Demography | 1 | 2006 | 435 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 931 | 0.020 |
Why?
|
| Idarubicin | 1 | 2007 | 446 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2008 | 621 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 891 | 0.020 |
Why?
|
| Precipitin Tests | 1 | 2004 | 329 | 0.020 |
Why?
|
| Bone Density Conservation Agents | 1 | 2006 | 198 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 2063 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2007 | 424 | 0.020 |
Why?
|
| Pelvic Exenteration | 1 | 2005 | 108 | 0.020 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2004 | 53 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2004 | 198 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2005 | 272 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 2330 | 0.010 |
Why?
|
| Cell Communication | 1 | 2007 | 509 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2004 | 198 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2004 | 173 | 0.010 |
Why?
|
| Base Sequence | 1 | 2010 | 4917 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2006 | 1062 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 2927 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 2315 | 0.010 |
Why?
|
| Receptors, Neuropeptide | 1 | 2002 | 27 | 0.010 |
Why?
|
| Premenopause | 1 | 2003 | 131 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2006 | 1519 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 665 | 0.010 |
Why?
|
| Cyclohexanes | 1 | 2002 | 38 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2002 | 300 | 0.010 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2002 | 86 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 840 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2007 | 1038 | 0.010 |
Why?
|
| Dactinomycin | 1 | 2002 | 145 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2006 | 649 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2006 | 850 | 0.010 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2002 | 222 | 0.010 |
Why?
|
| Transgenes | 1 | 2004 | 557 | 0.010 |
Why?
|
| Prevalence | 2 | 2001 | 3260 | 0.010 |
Why?
|
| Cystectomy | 1 | 2006 | 623 | 0.010 |
Why?
|
| Immunoassay | 1 | 2002 | 216 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2001 | 33 | 0.010 |
Why?
|
| Platelet Count | 1 | 2003 | 490 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2006 | 1234 | 0.010 |
Why?
|
| Acute Disease | 1 | 2007 | 2422 | 0.010 |
Why?
|
| Androgens | 1 | 2004 | 511 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 1538 | 0.010 |
Why?
|
| Uterus | 1 | 2006 | 678 | 0.010 |
Why?
|
| Epidemiologic Studies | 1 | 2001 | 60 | 0.010 |
Why?
|
| Models, Anatomic | 1 | 2002 | 154 | 0.010 |
Why?
|
| Child | 4 | 2007 | 29154 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 1099 | 0.010 |
Why?
|
| Chemoprevention | 1 | 2002 | 241 | 0.010 |
Why?
|
| Reoviridae Infections | 1 | 2000 | 6 | 0.010 |
Why?
|
| Organ Size | 1 | 2002 | 690 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 6086 | 0.010 |
Why?
|
| Finger Joint | 1 | 1999 | 12 | 0.010 |
Why?
|
| Etoposide | 1 | 2002 | 870 | 0.010 |
Why?
|
| Wrist Joint | 1 | 1999 | 30 | 0.010 |
Why?
|
| Hip Joint | 1 | 1999 | 54 | 0.010 |
Why?
|
| Hemochromatosis Protein | 1 | 1999 | 23 | 0.010 |
Why?
|
| Geography | 1 | 2000 | 140 | 0.010 |
Why?
|
| Animal Feed | 1 | 2000 | 81 | 0.010 |
Why?
|
| Population Density | 1 | 1999 | 38 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2006 | 2803 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2007 | 1818 | 0.010 |
Why?
|
| Opsonin Proteins | 1 | 1999 | 15 | 0.010 |
Why?
|
| Anopheles | 1 | 1999 | 28 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 1999 | 91 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 1360 | 0.010 |
Why?
|
| Lymphoma, Follicular | 1 | 2004 | 587 | 0.010 |
Why?
|
| Twin Studies as Topic | 1 | 1998 | 17 | 0.010 |
Why?
|
| Food | 1 | 2000 | 146 | 0.010 |
Why?
|
| Forecasting | 1 | 2002 | 694 | 0.010 |
Why?
|
| Pelvic Pain | 1 | 1999 | 48 | 0.010 |
Why?
|
| Immunity, Mucosal | 1 | 1999 | 108 | 0.010 |
Why?
|
| Methotrexate | 1 | 2002 | 999 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 1162 | 0.010 |
Why?
|
| Hand | 1 | 1999 | 170 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1999 | 409 | 0.010 |
Why?
|
| Knee Joint | 1 | 1999 | 161 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2004 | 1694 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2006 | 1270 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1999 | 334 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2006 | 1756 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2004 | 1459 | 0.010 |
Why?
|
| Menorrhagia | 1 | 1999 | 66 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2002 | 393 | 0.010 |
Why?
|
| United Kingdom | 1 | 1998 | 257 | 0.010 |
Why?
|
| Saliva | 1 | 1999 | 231 | 0.010 |
Why?
|
| Vincristine | 1 | 2002 | 1511 | 0.010 |
Why?
|
| Infant | 2 | 2007 | 13310 | 0.010 |
Why?
|
| Morbidity | 1 | 1999 | 397 | 0.010 |
Why?
|
| Leiomyoma | 1 | 1999 | 145 | 0.010 |
Why?
|
| Ovariectomy | 1 | 1999 | 330 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 1999 | 644 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1998 | 290 | 0.010 |
Why?
|
| Age Distribution | 1 | 1999 | 698 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2002 | 589 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2006 | 2359 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2007 | 16273 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2002 | 925 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 1998 | 602 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 1999 | 417 | 0.010 |
Why?
|
| Endometriosis | 1 | 1999 | 214 | 0.010 |
Why?
|
| Radiography | 1 | 1999 | 1904 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 1021 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2002 | 1648 | 0.010 |
Why?
|
| Endoscopy | 1 | 1998 | 479 | 0.010 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1998 | 436 | 0.010 |
Why?
|
| Uterine Neoplasms | 1 | 1999 | 545 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2007 | 8223 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1998 | 1005 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2004 | 1664 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2002 | 2086 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2004 | 3251 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 1998 | 622 | 0.010 |
Why?
|
| Clinical Competence | 1 | 1999 | 1270 | 0.010 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1990 | 14 | 0.010 |
Why?
|
| Ventilation | 1 | 1990 | 20 | 0.010 |
Why?
|
| Aging | 1 | 1999 | 1582 | 0.010 |
Why?
|
| North Carolina | 1 | 1990 | 125 | 0.010 |
Why?
|
| Asparaginase | 1 | 1990 | 184 | 0.010 |
Why?
|
| Cell Division | 1 | 1990 | 2489 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 2001 | 5542 | 0.000 |
Why?
|
| DNA, Neoplasm | 1 | 1990 | 1910 | 0.000 |
Why?
|